Surrogate end points in heart failure

Journal of the American College of Cardiology

Volumn 39, Issue 9, 2002, Pages 1414-1421

  Anand, Inder S ^a,c   Florea, Viorel G ^a   Fisher, Lloyd ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CLINICAL TRIALS; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EXERCISE TEST; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; NOREPINEPHRINE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RESEARCH DESIGN; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0036569112     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01773-4     Document Type: Review

References (82)

1. Predictors of readmission among elderly survivors of admission with heart failure
2. Early readmission of elderly patients with congestive heart failure
3. Role of surrogate end points in the evaluation of drugs for heart failure
4. Surrogates, semantics, and sensible public policy
5. Surrogate end points in clinical trials: Are we being misled?
6. Patients' self-assessment of their congestive heart failure: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire
7. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo
8. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin-converting enzyme inhibitor? Results of the Flosequinan-ACE inhibitor Trial (FACET)
9. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial
10. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
11. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
12. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan
13. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study
14. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death
15. Surrogate endpoints in clinical trials: Definition and operational criteria
16. A regulatory authority's opinion about surrogate endpoints
17. Surrogate endpoints in clinical trials: Cardiovascular diseases
18. Statistical validation of intermediate endpoints for chronic diseases
19. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research
20. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study
21. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure
22. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)
23. Ventricular premature beats and mortality after myocardial infarction
24. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
25. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs
26. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
27. QT dispersion and sudden unexpected death in chronic heart failure
28. Autonomic nervous system and sudden cardiac death
29. Neural activity and ventricular fibrillation
30. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction
31. Can drug effects on mortality in heart failure be predicted by any surrogate measure?
32. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
33. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction
34. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure
35. The 6-min walk and peak oxygen consumption in advanced heart failure: Aerobic capacity and survival
36. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?
37. The prognostic value of exercise capacity: A review of the literature
38. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure
39. Respiratory gas exchange in the assessment of patients with impaired ventricular function
40. Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization
41. Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure
42. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization
43. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association
44. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II
45. Double-blind placebocontrolled study of the efficacy of flosequinan in patients with chronic heart failure. REFLECT study
46. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
47. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II
48. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
49. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
50. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
51. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) investigators
52. Heart Failure - MOXCON (Moxonidine for Congestive Heart Failure)
53. Baseline and three-month change in systemic venous norepinephrine as predictors of clinical outcomes in the BEST trial investigators
54. Prognostic importance of a trial natriuretic peptide in patients with chronic heart failure
55. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32
56. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
57. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
58. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
59. B-type natriuretic peptide in the diagnosis and management of congestive heart failure
60. B-type natriuretic peptide levels: A potential novel "white count" for congestive heart failure
61. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
62. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study
63. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations
64. Ventricular enlargement and reduced survival after myocardial infarction
65. Left ventricular end-systolic volume as the major determinant of survival after recovery, from myocardial infarction
66. Factors influencing the one-year mortality, of dilated cardiomyopathy
67. Impact of left ventricular cavity size on survival in advanced heart failure
68. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II
69. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study)
70. Heart volume and cardiovascular mortality. A 16-year follow-up study of 1984 healthy middle-aged men
71. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction
72. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril
73. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril: Information from the Survival And Ventricular Enlargement (SAVE) trial
74. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy
75. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
76. Antiremodeling effects on the left ventride during beta-blockade with metoprolol in the treatment of chronic heart failure
77. Effects of carvedilol on left ventricular remodeling in patients following acute myocardial infarction: The CAPRICORN echo substudy
78. Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: The effect of captopril and xamoterol
79. Xamoterol in severe heart failure
80. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure
81. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure